The Technical Analyst
Ovid Therapeutics Inc [OVID]
Exchange: Nasdaq Global Select Sector: Healthcare Industry: Biotechnology
Stock Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-0.96% $3.11
Last updated: 21 Jan 2022 @ 12:13 pm
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 211.77 mill |
| EPS: | 1.839 |
| P/E: | 1.691 |
| Earnings Date: | Mar 14, 2022 |
| SharesOutstanding: | 68.09 mill |
| Avg Daily Volume: | 0.213 mill |
| RATING 2022-01-20 |
|---|
| B+ |
| Buy |
| RATING DETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/20 | 3/20 | 4/20 | 1/21 | 2/21 | 3/21 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.02x |
| Company: PE 1.691 | sector: PE 82.90 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE 1.691 | industry: PE 872.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$4.32 (38.99%) $1.213 |
| Date: 2022-01-21 |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-10-06 | Fitzgerald Kevin Joseph | Buy | 30 000 | Stock Option (Right to Buy) |
| 2021-07-14 | Rakhit Amit | Buy | 34 017 | Common Stock |
| 2021-07-14 | Rakhit Amit | Sell | 34 017 | Common Stock |
| 2021-07-14 | Rakhit Amit | Buy | 34 017 | Stock Option (Right to Buy) |
| 2021-07-09 | Poole Robert Michael | Buy | 30 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 82.27 |
| Last 94 transactions |
| Buy: 8 674 562 | Sell: 97 723 |
Forecast:
13:52 - $3.11
Live Trading Signals (every 1 min)
Forecast 1: 12:22 - $3.13
Forecast 2: 13:12 - $3.12
Forecast 3: 13:52 - $3.11
SCORE
-6.50
Sell
-6.50
Sell
Score Algorithm Version: 1.0b
Last version updated: Wed 15th Dec 2021
Last version updated: Wed 15th Dec 2021
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.11 (-0.96% ) |
| Volume | 0.123 mill |
| Avg. Vol. | 0.213 mill |
| % of Avg. Vol | 57.91 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OVID
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
| Date | Signal | @ | Closed | % | Jan 21 - 17:03 | sell | $3.13 | N/A | Active |
|---|
OVID
Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 54 full-time employees. The firm is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.
Latest Press Releases
2022-01-03 06:30:00 - Press Release
Ovid Therapeutics Expands Epilepsy Franchise With Novel Kcc2 Activators
New york, jan. 03, 2022 (globe newswire) -- ovid therapeutics inc. (nasdaq: ovid), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the company has entered into an exclusive license agreement with astrazeneca for a library of early-stage small molecules targeting the kcc2 transporter, including lead candidate, ov350. the company seeks to optimize and accelerate development of these kcc2 transporter activators in epilepsies and potentially other neuropathic conditions.
2021-11-10 08:30:00 - Press Release
Ovid Therapeutics Reports Third Quarter 2021 Business Update, Corporate Highlights And Financial Results
New york, nov. 10, 2021 (globe newswire) -- ovid therapeutics inc. (nasdaq: ovid), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today provided a business update and reported corporate highlights and financial results for the quarter ended september 30, 2021.
2021-10-07 08:30:00 - Press Release
Ovid Therapeutics Appoints Dr. Kevin Fitzgerald To Board Of Directors
New york, oct. 07, 2021 (globe newswire) -- ovid therapeutics inc. (nasdaq: ovid), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed kevin fitzgerald, ph.d., to its board of directors.
2021-08-16 08:00:00 - Press Release
Ovid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights
New york, aug. 16, 2021 (globe newswire) -- ovid therapeutics inc. (nasdaq: ovid), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases, today reported financial results for the quarter ended june 30, 2021. the company also provided an overview of recently announced leadership appointments that will guide and execute its strategy.
2021-07-08 16:30:00 - Press Release
Ovid Therapeutics Strengthens Board & Leadership Team To Focus Efforts On Expanding Its Neurosciences Capabilities
Dr. michael poole to join the board of directors
Latest News
2021-10-07 08:30:00 - GlobeNewsWire
Ovid Therapeutics Appoints Dr. Kevin Fitzgerald to Board of Directors
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Kevin Fitzgerald, Ph.D., to its Board of Directors.
2021-07-08 16:30:00 - GlobeNewsWire
Ovid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities
2021-06-18 17:09:55 - Seeking Alpha
Ovid Therapeutics: Good Entry Point For Investors
There are promising results for OV-935 in patients with Dravet Syndrome, with questionable results in patients with Lennox-Gastaut Syndrome (LGS). Pipeline drug OV-935 shows high revenue potential.
2021-05-20 12:02:32 - Zacks Investment Research
3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem
2021-05-12 08:00:00 - GlobeNewsWire
Ovid Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 9:10 a.m. ET.
2021-04-30 11:37:02 - InvestorPlace
HMNY Stock & 7 Other Reddit Penny Stocks Hoping for a Takeover
The odds of bankrupt HMNY stock getting acquired may be slim, but for these seven other Reddit penny stocks it's definitely a possibility. The post HMNY Stock & 7 Other Reddit Penny Stocks Hoping for a Takeover appeared first on InvestorPlace.
2021-03-30 09:20:26 - Pulse2
OVID Stock Price Increased Over 5% Pre-Market: Why It Happened
The stock price of Ovid Therapeutics Inc. (NASDAQ: OVID) increased by over 5% pre-market. This is why it happened.
2021-03-10 11:54:25 - InvestorPlace
8 Biotech Penny Stocks for Investors to Watch
Low-priced biotechs have sold off recently, but there could still be potential in these picks. Here are eight penny stocks to consider.
2021-03-03 11:38:56 - InvestorPlace
OVID Stock News: The Big Deal That Has Ovid Therapeutics Rocketing Higher Today
Ovid Therapeutics (OVID) stock is soaring higher on Wednesday after announcing a massive deal with Takeda Pharmaceutical (TKPHF). The post OVID Stock News: The Big Deal That Has Ovid Therapeutics Rocketing Higher Today appeared first on InvestorPlace.
2021-03-03 10:17:46 - Benzinga
Why Ovid, KemPharm, Sorrento, Aquestive Are Rallying
Ovid Therapeutics Inc. (NASDAQ: OVID), KemPharm Inc (NASDAQ: KMPH), Aquestive Therapeutics Inc (NASDAQ: AQST) and Sorrento Therapeutics, Inc. (NASDAQ: SRNE) were among the health care gainers in Wednesday's premarket session. Here's what investors need to know.